Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...

About last summer

Last summer, we have kept you informed on industry trends by providing you with great content to stay on top of innovation even on holiday.
See all of the weekly activities here >>